An independent Data Monitoring Committee reviewed unblinded interim data from approximately 37% of Actinogen’s pivotal XanaMIA Alzheimer’s disease trial and recommended the study continue without amendment. The interim cut included 136 participants with at least one efficacy datapoint and 52 who completed the full 36-week treatment period. The trial is fully enrolled at 247 patients on Xanamem 10 mg or placebo, with last patient visit expected in September and topline results slated for November 2026.
The core update is continuity: no safety signal or futility boundary triggered a stop or redesign, preserving the original statistical plan and timelines. Actinogen plans an open-label extension offering up to 25 months of Xanamem to all completers, intended to build longer-term safety and functional data. The company also outlined a second, larger global pivotal study to begin in 2027, alongside open-label and clinical pharmacology work, following alignment with FDA in a prior Type C meeting on a “streamlined” path. Scientific advice from EMA is expected in Q2, signaling a bid for cross-regional regulatory convergence. Financing is described as sufficient beyond the November readout following a placement and share purchase plan.
Strategically, Actinogen is positioning an oral, once-daily small molecule that targets brain cortisol synthesis via 11β-HSD1 inhibition against a market defined by anti-amyloid antibodies and intensive site infrastructure. A DMC “continue” decision is a necessary but not sufficient hurdle; it implies no early efficacy collapse and no material safety concerns in the first third of data, while avoiding a mid-course sample-size re-estimation or protocol change that could complicate interpretation. The planned second pivotal indicates the company is leaning into a conventional two-study efficacy package rather than a single pivotal with confirmatory evidence, a prudent posture given the regulatory bar in Alzheimer’s has been reset by agents demonstrating CDR-SB and functional benefits alongside biomarker effects.
For sites and CROs, the operational profile is favorable. Oral dosing without infusion logistics reduces chair time and monitoring overhead, broadens the pool of community sites, and can ease recruitment in regions where infusion capacity is constrained. The open-label extension should aid retention and lower post-topline attrition, but it extends staff and rater commitments into 2028, heightening risks of rater drift and turnover. Centralized rater training, consistency checks, and potential use of remote assessments for function and activities of daily living will be pivotal to data quality. If the pivotal did not require amyloid biomarker confirmation, that may have accelerated enrollment and reduced screen fails; however, regulators increasingly expect biomarker-defined populations, and mismatches here could complicate label negotiations or necessitate biomarker-stratified analyses in the next study.
Key watch items over the next nine months include clarity on the primary endpoint hierarchy (likely centered on CDR-SB with cognitive and ADL measures), the baseline disease stage mix (mild vs mild-to-moderate and its dilution risk), and whether background anti-amyloid therapy was permitted—now a live question for placebo-controlled designs in standard-of-care environments. The EMA advice in Q2 will be an early read on European expectations for population definition and endpoints. Post-topline, the size and geography of the 2027 confirmatory trial, biomarker strategy, and any combination or add-on design choices will signal how Actinogen intends to navigate a landscape shifting toward background therapy and payer scrutiny of functional outcomes. The interim decision buys time and preserves momentum; the next inflection will be whether November delivers a clinically credible, operationally reproducible signal strong enough to underwrite the second pivotal and a path to broad adoption.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
